Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314

Benzinga · 1d ago
Canaccord Genuity analyst Whitney Ijem maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $303 to $314.